GH vs NEO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GH and NEO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GH and NEO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).

Full GH guide

NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026.

Full NEO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.
• NEO drivers: Mix shift into NGS carries the revenue line; Margin discipline turning into real adjusted EBITDA.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. For NEO, gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GH if you believe its drivers more; NEO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GH and NEO guides.

GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades on a high price-to-sales multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The share price is volatile and moved sharply in mid-2026 on reimbursement news (including a July 2026 UnitedHealth coverage decision for Shield), which is why the timeline to 2027 cash-flow breakeven and the pace of Shield adoption matter more than any single quarter.

NEO. With no trailing earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.7 times trailing revenue and roughly 40 times the midpoint of guided 2026 adjusted EBITDA. That second figure only looks reasonable if margin expansion continues for several more years, which is the crux of the debate on the name. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from $5.94 to $16.92 over the past 52 weeks.

Headline figures (approximate, July 2026): GH shows revenue (q1 2026 quarterly) ~$302 million, up 48% year over year, 2026 revenue guidance (full year) ~$1.30 to $1.32 billion (~32 to 34% growth), adjusted ebitda (q1 2026) ~-$59 million loss (still unprofitable), cash and equivalents ~$1.2 billion at quarter end; NEO shows revenue (ttm) ~$766M (four quarters ended June 30, 2026), q2 2026 revenue ~$202M, up ~11% year over year, market cap ~$2.1B (~$16 per share on ~128.5M shares), price to sales ~2.7x trailing; enterprise value ~$2.3B, or ~3.0x sales.

GH and NEO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GH and NEO exposure against your real portfolio. It is not an investment adviser.